Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

Blood

Volumn 97, Issue 5, 2001, Pages 1427-1434

  Bellamy, William T ^a,b   Richter, Lynne ^a   Sirjani, Davuud ^a   Roxas, Concepcion ^a   Glinsmann Gibson, Betty ^a   Frutiger, Yvette ^a   Grogan, Thomas M ^a   List, Alan F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; METHYLCELLULOSE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; CELL RENEWAL; CONTROLLED STUDY; ERYTHROID PRECURSOR CELL; GENE; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; LYMPHOID CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION;

EID: 0035283119     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.5.1427     Document Type: Article

References (49)

1. Pharmacological differentiation and antiapoptotic therapy in myelodysplastic syndromes
2. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors
3. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome
4. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
5. Novel insights into biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines
6. Overexpression of tumor necrosis factor (TNF)-α and interferon (INF)-α by bone marrow cells from patients with myelodysplastic syndromes
7. A role for tumor necrosis factor-alpha, fas and fas-ligand in marrow failure associated with myelodysplastic syndrome
8. Oxidative DNA damage in CD34 myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumor necrosis factor-α concentration
9. Clinical applications of research on angiogenesis
10. Tumor angiogenesis
11. Expression of vascular endothelial growth factor (VEGF) and its receptors in hematopoietic malignancies
12. Vascular endothelial growth factor is a secreted angiogenic mitogen
13. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
14. Proteolytic remodeling of extracellular matrix
15. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice
16. KDR receptor: A key marker defining hematopoietic stem cells
17. Processing of tumor necrosis factor-α precursor by metalloproteinases
18. A metalloproteinase disintegrin that releases tumor necrosis factor-alpha from cells
19. Metalloproteinase-mediated release of human Fas ligand
20. The fms-like tyrosine kinase receptor, a receptor for vascular endothelial growth factor
21. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
22. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor fit-1
23. Macrophages and angiogenesis
24. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor
25. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
26. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
27. Angiogenesis in myelodysplastic syndromes
28. Methodology of long-term culture of human haemopoietic cells
29. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
30. Multivariate analysis of prognostic factors in acute myeloid leukemia: Value of clonogenic leukemic cell properties
31. Mast cell growth factor (C-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome
32. Kineticmode, automated double-labeled immunohistochemistry and in situ hybridization in diagnostic pathology
33. Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus RNA and protein in paraffin embedded tissue biopsies
34. Combined in situ hybridization for automated detection of cytomegalovirus and p53
35. Proposals for the classification of the myelodysplastic syndromes
36. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
37. Evidence of increased angiogenesis in patients with acute myeloid leukemia
38. The binding of vascular endothelial growth factor to its receptors is dependent of cell surface associated heparin-like molecules
39. Heparan-sulfate bound growth factors: A mechanism for stromal cell mediated haemopoiesis
40. Dual regulation of vascular endothelial cell growth factor bioavailability by genetic and proteolytic mechanisms
41. The carboxyl-terminal domain (111- 165) of vascular endothelial growth factor is critical for its mitogenic potency
42. 165
43. Neuropilin-1 is expressed on bone marrow stromal cells: A novel interaction with hematopoietic cells?
44. Expression of VEGFR-2 and AC133 by circulating human CD34- cells identifies a population of functional endothelial cells
45. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
46. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kB activation in hemopoietic progenitor cells
47. Mutant ras oncogenes up-regulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
48. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis
49. Endothelial cells in physiology of vascular disorders